Ormutivimab
Based on 1 publication(s) in Google Scholar
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95%
- No. CAS: 2449086-91-1
- Peso molecular:146.1 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ormutivimab
More
Actividad biológica
Human IgG1 lambda2
Virus
RABVG
Ormutivimab (20 IU/kg, 100 IU/kg; i.m.; single dose) protects challenged Kunming mice against various rabies virus[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c mice challenge model with rabies virus[1]
-
Dosage:20 IU/kg, 100 IU/kg
-
Administration:Intramuscular injection; single dose after 4 hr after infection
-
Result:Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 2449086-91-1
-
Appearance Liquid
-
Peso molecular 146.1 kDa
-
Color Colorless to light yellow
-
SMILES
[Ormutivimab]
-
Synonyms
NM57; rhRIG
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Transbound Emerg Dis
A Fully Human Derived Monoclonal Antibody Provides Potent Pre- and Postexposure Protection Against Rabies Virus. [Abstract]2026;2026(1):e3021186. PMID: 42318992
Pureza y Documentación
-
Ficha de datos (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267. [Content Brief]
[2]. Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ormutivimab Related Classifications
HY-P99792 Related Classifications
Powered by Bioz